Get the Stockscreener App
3.83
10.37%
0.36
Pre-market:
4.60
0.77
+20.10%
Dbv Technologies Adr stock is traded at $3.83, with a volume of 1.25M.
It is up +10.37% in the last 24 hours and up +9.68% over the past month.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
See More
Previous Close:
$3.47
Open:
$3.66
24h Volume:
1.25M
Relative Volume:
4.87
Market Cap:
$78.58M
Revenue:
-
Net Income/Loss:
$-102.09M
P/E Ratio:
-3.6476
EPS:
-1.05
Net Cash Flow:
$-108.72M
1W Performance:
+17.85%
1M Performance:
+9.68%
6M Performance:
-1.92%
1Y Performance:
-58.82%
1-Day Range:
$3.4001
$3.90
1-Week Range:
$3.3034
$3.90
52-Week Range:
$2.2045
$9.486
Dbv Technologies Adr Stock (DBVT) Company Profile
Name
Dbv Technologies Adr
Sector
Industry
Phone
33(0)155427878
Address
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Compare DBVT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
3.83 | 78.58M | 0 | -102.09M | -108.72M | -1.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.11 | 106.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.59 | 80.61B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
649.26 | 38.82B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.55 | 31.03B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.15 | 29.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-04-23 | Upgrade | Societe Generale | Hold → Buy |
| Dec-16-22 | Downgrade | Goldman | Neutral → Sell |
| May-10-22 | Downgrade | Goldman | Buy → Neutral |
| Sep-14-21 | Upgrade | Societe Generale | Hold → Buy |
| Jan-22-21 | Downgrade | Societe Generale | Hold → Sell |
| Nov-02-20 | Upgrade | Societe Generale | Sell → Hold |
| Aug-06-20 | Downgrade | Societe Generale | Buy → Sell |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-17-20 | Downgrade | Stifel | Buy → Hold |
| Jan-09-20 | Upgrade | Stifel | Hold → Buy |
| Dec-16-19 | Initiated | Citigroup | Buy |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Jun-17-19 | Initiated | Goldman | Buy |
| Dec-20-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-20-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-20-18 | Downgrade | Jefferies | Buy → Hold |
| Dec-20-18 | Downgrade | Stifel | Buy → Hold |
| Oct-31-17 | Upgrade | Societe Generale | Sell → Hold |
| Oct-24-17 | Downgrade | Societe Generale | Buy → Sell |
| Oct-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-23-17 | Initiated | Deutsche Bank | Buy |
| Mar-16-17 | Upgrade | Societe Generale | Hold → Buy |
| Sep-26-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-03-15 | Initiated | Barclays | Overweight |
| Oct-23-15 | Initiated | BofA/Merrill | Buy |
View All
Dbv Technologies Adr Stock (DBVT) Latest News
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
StockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT) - Defense World
DBV Technologies Reports Positive Phase 3 Study Results - TipRanks
DBV Technologies announces three-year results from EPITOPE trial - TipRanks
DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study - The Manila Times
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Flat for Week - MSN
DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com - Defense World
DBV Technologies (NASDAQ:DBVT) Share Price Crosses Below 50 Day Moving AverageWhat's Next? - MarketBeat
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Rise in Monday Trading - MSN
European Equities Traded in the US as American Depositary Rise in Thursday Trading - MSN
European Equities Traded in the US as American Depositary Edge Lower in Thursday Trading - MSN
European Equities Traded in US as American Depositary Receipts Tread Water Friday, Up 3% for Week - MSN
European Equities Traded in the US as American Depositary Edge Higher in Thursday Trading - MSN
DBV Technologies (NASDAQ:DBVT) Now Covered by Analysts at StockNews.com - Defense World
Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading - MSN
Oil Stocks Lead European Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday Trading - MSN
DBV Technologies enhances severance terms for top executives - Investing.com
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading - MSN
DBV Technologies' SWOT analysis: viaskin peanut stock shows promise amid challenges - Investing.com
European Equities Traded in the US as American Depositary Lower in Tuesday Trading - MSN
Financial Survey: Apogee Therapeutics (NASDAQ:APGE) versus DBV Technologies (NASDAQ:DBVT) - Defense World
European Equities Traded in the US as American Depositary Receipts Slightly Higher in Wednesday Trading - MSN
Wall Street Poised To Open Lower A Day After Nasdaq's Record Close Above 20,000: Expert Flags 'Deterioration Under The Surface' As 117 S&P 500 Stocks Hit New Monthly Lows - Benzinga
DBV Technologies jumps on US FDA approval of peanut allergy treatment - XM
DBV Confirms Alignment with U.S. FDA on Accelerated - GlobeNewswire
DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 13 Years-Old - The Manila Times
DBV Technologies Secures FDA Fast-Track for Revolutionary Peanut Allergy Patch in Toddlers - StockTitan
DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old - Yahoo Finance
European Equities Traded in the US as American Depositary Tread Water in Friday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading - MSN
DBV Technologies' SWOT analysis: peanut allergy treatment stock faces funding hurdles - Investing.com
DBV Technologies S.A. (NASDAQ:DBVT) Short Interest Down 5.3% in November - MarketBeat
DBV technologies S.A. (ADR) Revenue Breakdown – SWB:DBV1 - TradingView
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading - MSN
European Equities Traded in the US as American Depositary Decline in Tuesday Trading - MSN
Dbv technologies chief medical officer sells shares worth $1,269 - Investing.com
European Equities Traded in the US as American Depositary Rise Thursday - MSN
DBV Technologies (STU:DBV0) Shares Outstanding (EOP) : 96.20 Mil (As of Sep. 2024) - GuruFocus.com
DBV Technologies (STU:DBV0) Financial Strength : 7 (As of Sep. 2024) - GuruFocus.com
DBV Technologies (STU:DBV0) 3-Year EBITDA Growth Rate : 29.70% (As of Sep. 2024) - GuruFocus.com
Dbv Technologies Adr Stock (DBVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dbv Technologies Adr Stock (DBVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mohideen Pharis | Chief Medical Officer |
Nov 22 '24 |
Sale |
0.53 |
342 |
181 |
111,675 |
| Mohideen Pharis | Chief Medical Officer |
Nov 21 '24 |
Sale |
0.54 |
2,350 |
1,269 |
112,017 |
| Mohideen Pharis | Chief Medical Officer |
Jul 29 '24 |
Sale |
0.98 |
1,785 |
1,749 |
79,367 |
| Mohideen Pharis | Chief Medical Officer |
May 24 '24 |
Sale |
1.36 |
660 |
898 |
81,152 |
| Mohideen Pharis | Chief Medical Officer |
May 22 '24 |
Sale |
1.38 |
382 |
527 |
81,812 |
| Tasse Daniel | CHIEF EXECUTIVE OFFICER |
Mar 08 '24 |
Buy |
0.83 |
17,094 |
14,188 |
17,094 |
| Ndu Adora | Director |
Feb 06 '24 |
Buy |
0.89 |
1,825 |
1,624 |
1,825 |
0.08%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):